Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The somatotropic axis is a hormonal signaling pathway connecting the hypothalamus, anterior pituitary gland, and peripheral tissues. It primarily controls the production and effects of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). GH is secreted by somatotropes in the pituitary gland in response to hypothalamic signals (growth hormone-releasing hormone and somatostatin), enters circulation, and promotes IGF-1 synthesis in tissues, mainly the liver. IGF-1 acts systemically to modulate growth, metabolism, tissue repair, and aging. Dysfunction of this axis can contribute to growth abnormalities, metabolic and cardiovascular diseases, certain cancers, and aging-related conditions.
Mechanisms pertain to targeting receptors or hormone signaling within the axis: Agonism/antagonism of GH and IGF-1 receptors; Modulation of GH secretion via GHRH or somatostatin pathways.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hypothalamic–pituitary–somatotropic axis (HPS axis).